Dr. Prof Ranjit Manchanda

About Dr. Prof Ranjit Manchanda

Professor Ranjit Manchanda is a leading Gynaecological Oncologist practising at Barts and The Royal London Hospital, and Professor of Gynaecological Oncology at the Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary University of London.
He completed his PhD in Gynaecological Oncology at University College London (UCL). He undertook subspecialty training in gynaecological oncology at UCLH and St Bartholomew’s Hospital (Barts Health), following an NIHR Clinical Academic Lectureship.
Professor Manchanda is an NHS Innovation Accelerator (NIA) Fellow and leads the high-risk women’s Precision Prevention service at Barts Health. He also chairs the London Cancer High-Risk Gynaecological Cancer MDT and is a member of the NCRI Ovarian Cancer Surgical Subgroup.
He has a strong interest in ultra-radical debulking surgery for ovarian cancer and minimal access surgery, and serves as co-Lead for the Cancer Prevention Theme at Barts CRUK Cancer Centre.
Professor Manchanda is actively involved in education, leading the Integrated Academic Training Programme for Obstetrics & Gynaecology in London, and the RCOG Advanced Professional Module in Clinical Research.
He is a member of the International Gynaecological Cancer Society (IGCS) Education Steering Committee and Deputy Director of the Barts Health RCOG sub-speciality training programme. He has previously served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and was a Council Member of the European Society of Gynaecological Oncology (ESGO).
In addition to his clinical and academic work, Professor Manchanda’s research focuses on targeted precision prevention strategies, including population-based germline testing, risk stratification, and cancer prevention approaches.

Conditions treated by Dr. Prof Ranjit Manchanda

Cervical cancer
Heavy periods/menorrhagia treatment
Management of high-risk women, e.g. BRCA, lynch Syndrome, Cowden's Syndrome, RAD51C, RAD51D, BRIP1, PALB2
Ovarian cancer
Vulval cancer
Vaginal cancer
Endometrial cancer
Cervical cancer
Management of high-risk women

Area of Interest

Gynaecology
Oncology

Qualification

MBBS & MD from All India Institute of Medical Sciences (AIIMS), New Delhi, India (1990s)
MRCOG
PhD in Gynaecological Oncology from University College London (UCL), focusing on gynaecological oncology

Work Experiences

Completed NIHR Clinical Academic Lectureship at University College London (UCL).
Subspecialty training in Gynaecological Oncology at UCLH and St Bartholomew’s Hospital (Barts Health).
Former President of the European Network of Young Gynaecological Oncologists (ENYGO).
Former Member of the European Society of Gynaecological Oncology (ESGO) Council (2011–2013).
Deputy Director of the Barts Health RCOG sub-speciality training programme in gynaecological oncology.

Global Team of Board Certified Surgeons and Medical Specialists
Written Second Opinion report delivered within 5 days
Option to avail the Video Consultation with the Lead Doctor of the board

Access Our most trusted Medical Second Opinion

Telemedicine Doctors

Do you know?

You can book a video consultation with Dr. Prof Ranjit Manchanda on our platform

Consult Online

CERTIFICATIONS (3)

NHS Innovation Accelerator Fellowship Award (Mar 2019)
Helen Harris Memorial Trust Travelling Fellowship Award (2011)
Indian Council of Medical Research (ICMR) Fellowship award (2000 - 2001)

MEMBERSHIPS (7)

Membership of the Royal College of Obstetricians and Gynaecologists
International Gynaecological Cancer Society (IGCS)
European Society of Gynaecological Oncology (ESGO)
Royal College of Obstetricians and Gynaecologists (RCOG)
National Cancer Research Institute (NCRI)
London School of Obstetrics & Gynaecology, Health Education England
Barts Health NHS Trust

RESEARCH PAPERS AND PUBLICATIONS (3)

Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 2019.
Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, Hopper JL, MacInnis RJ, Turnbull C, Ramus SJ, Gayther SA, Pharoah PDP, Menon U, Jacobs I, Legood R. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst. 2018.
Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. J Natl Cancer Inst. 2014.

Share Your Experience about Dr. Prof Ranjit Manchanda

Write Your Review

PROCEDURES

Cervical Cancer Treatment
Chemotherapy
Hormonal Therapy
Immunotherapy
Ovarian Cancer Treatment
Uterine Cancer Treatment
Vaginal Cancer Treatment
Vulvar Cancer Treatment

FREQUENTLY ASKED QUESTIONS

Is Dr. Prof. Ranjit Manchanda offering teleconsultations on the MediGence platform?

Dr. Prof Ranjit Manchanda is available to teleconsult on the MediGence platform.

How long is the consultation?

The consultation typically lasts between 15 and 30 minutes. It may exceed the estimated time, depending on the patient’s queries and the doctor's medical suggestions.

How soon can the consultation be organised?

We have Medical specialists and board-certified doctors on our panel of doctors. The consultation will be organised within 24 to 48 hours or based on the availability of the doctor and the patient.

Is a follow-up consultation included in the consultation price?

No, the follow-up consultation fee is not included in the consultation price. The patient will be required to re-book the consultation.

How do I share my medical record with the doctor for review?

The option to share your medical records is available between the steps of the form provided to you on the website.

Can I book my procedure with the doctor post-consultation?

Yes. If you are satisfied with the consultation, you can proceed with treatment packages tailored to your diagnosis, with the assistance of our case managers.

Can you get an estimate for the procedure?

Yes. The cost estimate will be provided to you by our case manager, including the doctor’s opinion, the cost estimate, and crucial information about travelling to your medical destination.

FAQ's Related to Gynaecologist

What does a Gynaecological Oncologist specialise in?

A Gynaecological Oncologist specialises in the diagnosis and treatment of cancers affecting the female reproductive system, such as ovarian, cervical, uterine, vaginal, and vulvar cancers.

When should I see a Gynaecological Oncologist?

You should consult a Gynaecological Oncologist if you have abnormal Pap smear results, a family history of gynaecological cancers, unexplained pelvic pain, or a diagnosis of reproductive system cancer.

What types of treatments does a Gynaecological Oncologist provide?

They provide surgery (including radical and minimal access surgery), chemotherapy, radiation therapy, targeted therapies, and personalised cancer prevention strategies.

Do Gynaecological Oncologists perform genetic testing?

Yes, they often offer population-based germline testing to identify genetic mutations (e.g., BRCA1, BRCA2) that increase cancer risk, especially for patients with a family history of cancer.

What is Precision Prevention in Gynaecological Oncology?

Precision Prevention involves utilising genetic and clinical data to predict cancer risk and provide targeted screening, preventive measures, and early interventions for individuals at high risk.

Can Gynaecological Oncologists manage high-risk patients before cancer develops?

Yes, they specialise in managing high-risk patients through surveillance, genetic counselling, risk-reducing surgeries, and preventive strategies to reduce the likelihood of developing cancer.

Welcome To MediGence

Your Notifications